Recurrent pancreatic cancer patient treated by chemotherapy and focused ultrasound surgery. A case report.
We present a case of recurrent pancreatic cancer diagnosed by computer tomography (CT) and positron emission tomography(PET), 7 months after Whipple radical surgery in a 61-year-old female patient. The patient was successfully treated byfocused ultrasound surgery (FUS) by innovative high intensity focused ultrasound device. The patient had no complications.Multiple cycles of chemotherapy were done. Twelve months after FUS the new PET-CT showed no evidence of metabolite activezone in the area of ablation and no progression of disease. The presented case is unique according to the literature as a localrecurrence after radical surgery for pancreatic cancer, successfully managed by local FUS ablation and adjuvant chemotherapy. PMID: 32190856 [PubMed - as supplied by publisher]
Is pancreatic enzyme replacement therapy being underutilized in patients with chronic pancreatitis or pancreatic cancer?Alimentary Pharmacology &Therapeutics
n G Abstract Pendimethalin, one of the dinitroaniline group herbicides, is applied for controlling weeds in cereals, legumes and vegetable crops, and has been classified as possible human carcinogen. It is indicated that pendimethalin should arise risks of developing some cancer types; however, there is no data on the effects of pendimethalin on pancreatic cancer-induced inflammation. Injuries resulting from by acute pancreatitis attacks and inflammation are significant factors in the development of pancreatic cancer. Therefore, we investigated whether pendimethalin triggers inflammation as a mechanism of pancreat...
Researchers found that patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy.
l Sumit Sahni Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors in the world. Currently, there are no approved targeted therapies for PDAC. Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are known to be a major driver of PDAC progression, but it was considered an undruggable target until recently. Moreover, PDAC also suffers from drug delivery issues due to the highly fibrotic tumor microenvironment. In this perspective, we provide an overview of recent developments in targeting mutant KRAS and strategies to overcome drug delivery issues (e.g., nanoparticle delivery). Over...
AbstractIn the past years, a multitude of studies has been published in the field of pancreatic organogenesis to interrogate the critical regulators of endocrine lineage segregation. Preliminary, transcription factors are guiding the transcriptional hierarchy of the endocrine specified cells, underpinning the importance of open chromatin formation. Signaling pathways either inhibit or accelerate the transcriptional landscape of pancreatic organogenesis. Thus, the fine-tuned process in the former pancreatic multipotent progenitors in the mechanism of lineage segregation needs to be elucidated more precisely for unraveling t...
Publication date: May 2020Source: Chinese Journal of Natural Medicines, Volume 18, Issue 5Author(s): Xue-Ying LI, Homng TAO, Can JIN, Zhen-Yun DU, Wen-Feng LIAO, Qing-Jiu TANG, Kan DING
Publication date: Available online 21 May 2020Source: Cancer CellAuthor(s): Zhentian Wang, Simone Hausmann, Ruitu Lyu, Tie-Mei Li, Shane M. Lofgren, Natasha M. Flores, Mary E. Fuentes, Marcello Caporicci, Ze Yang, Matthew Joseph Meiners, Marcus Adrian Cheek, Sarah Ann Howard, Lichao Zhang, Joshua Eric Elias, Michael P. Kim, Anirban Maitra, Huamin Wang, Michael Cory Bassik, Michael-Christopher Keogh, Julien Sage
Conclusions: Despite being administered more frequently to patients with poor prognostic factors, postoperative chemotherapy after preoperative therapy and pancreatectomy for PDAC was of clinical benefit.
No abstract available
Conclusion: This paper provides new information on how prognosis following pancreatectomy for PDAC evolves over time, adjusting for the time the patient already survived, and for the patient's present disease status relative to recurrence.